Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial.
Arch Med Res. 2014 Jul;45(5):388-93. doi: 10.1016/j.arcmed.2014.05.003. Epub 2014 May 13.
Rodríguez-Moran M1, Guerrero-Romero F2 guerrero.romero at gmail.com
1 Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico.
2 Biomedical Research Unit, Mexican Social Security Institute, Durango, Mexico.
Magnesium Chloride containing 386 mg Mg
Both obese and normal weight individuals had similar benefit
|Systolic blood pressure||-2 mm||+4 mm|
|Diastolic blood pressure||-4 mm||+8 mm|
|Fasting glucose||-12%||-2% mg/dL|
- Search VitaminDWiki for HOMA-IR 86 items as of Oct 2014
- 4000 IU RCT reduces type 2 diabetes HOMA by 24% and CRP by 64% April 2010
- Overview Magnesium and vitamin D
- Overview Metabolic Syndrome and vitamin D
- Overview Diabetes and vitamin D contains the following summary
- Diabetes is 5X more frequent far from the equator
- Children getting 2,000 IU of vitamin D are 8X less likely to get Type 1 diabetes
- Obese people get less sun / Vitamin D - and also vitamin D gets lost in fat
- Sedentary people get less sun / Vitamin D
- Worldwide Diabetes increase has been concurrent with vitamin D decrease and air conditioning
- Elderly get 4X less vitamin D from the same amount of sun
Elderly also spend less time outdoors and have more clothes on
- All items in category Diabetes and Vitamin D
407 items: both Type 1 and Type 2
Vitamin D appears to both prevent and treat diabetes
- Appears that >2,000 IU will Prevent
- Appears that >4,000 IU will Treat , but not cure
- Appears that Calcium and Magnesium are needed for both Prevention and Treatment
which are just some of the vitamin D cofactors
The TOP Metabolic Syndrom articles are here:
BACKGROUND AND AIMS:
We undertook this study to determine the efficacy of oral magnesium supplementation in the improvement of the metabolic profile and blood pressure in metabolically obese, normal-weight (MONW) individuals.
A total of 47 MONW individuals with hypomagnesemia were enrolled in clinical a randomized double-blind placebo-controlled trial. Individuals in the intervention group received 30 mL of MgCl2 5% solution (equivalent to 382 mg of magnesium) and individuals in the control group 30 mL of placebo solution, once daily during 4 months. In the absence of obesity or overweight, the presence of fasting glucose levels ≥100 mg/dL, HOMA-IR index ≥3, triglyceride levels ≥150 mg/dL and/or systolic and diastolic blood pressure ≥140 and 90 mmHg defined the presence of the MONW phenotype. Hypomagnesemia was defined by serum magnesium concentration ≤1.8 mg/dL.
At basal conditions there were no significant differences between groups. At the end of follow-up, changes in the mean of systolic (-2.1 vs. 3.9% mmHg, p <0.05) and diastolic (-3.8 vs. 7.5% mmHg, p <0.05) blood pressures, HOMA-IR index (-46.5 vs. -5.4%, p <0.0001), fasting glucose (-12.3 vs. -1.8% mg/dL, p <0.05) and triglyceride levels (-47.4% vs. 10.1% mg/dL, p <0.0001) were significantly lower in the subjects who received MgCl2 compared with individuals in the control group.
Oral magnesium supplementation improves the metabolic profile and blood pressure of MONW individuals.
Copyright © 2014 IMSS. Published by Elsevier Inc. All rights reserved.